Novartis AG (NYSE: NVS) — Perfil da empresa, notícias e dados financeiros
Novartis AG is a multinational pharmaceutical company dedicated to developing innovative healthcare solutions, including vaccines.
Novartis AG
Novartis AG is a global healthcare company based in Basel, Switzerland, that researches, develops, manufactures, and markets innovative prescription medicines. The company focuses its commercial and development operations on primary therapeutic areas, including oncology, cardiovascular, renal and metabolic diseases, immunology, and neuroscience. Its organizational structure comprises Biomedical Research, which serves as the innovation engine for early-stage scientific discovery, and Development, which manages clinical trials and regulatory approval processes globally. The company distributes its commercialized pharmaceutical products to patients and healthcare institutions across approximately 120 countries worldwide.
Resumo
Operações
Produtos e/ou serviços de Novartis AG
- Oncology: Prescription pharmaceutical treatments for broad solid tumors and hematologic malignancies, utilizing targeted small molecules, biologics, radioligand therapies, and advanced cell and gene therapy platforms distributed across global clinical healthcare markets.
- Cardiovascular, Renal and Metabolic: Prescription pharmaceutical therapies targeting heart failure, dyslipidemia, acute hypertension, and chronic kidney diseases, supplying major hospital networks and outpatient care systems globally to manage severe cardiovascular and metabolic conditions.
- Immunology: Biologic and small-molecule prescription treatments for autoimmune and chronic inflammatory conditions, supplying healthcare systems worldwide with specialized systemic therapies for complex dermatological, severe rheumatological, and chronic gastrointestinal inflammatory disorders.
- Neuroscience: Specialized prescription pharmaceutical therapies for complex neuromuscular and neurodegenerative disorders, including targeted treatments for multiple sclerosis, spinal muscular atrophy, and rare neurological conditions distributed through specialized healthcare networks across international markets.
- Biomedical Research: Early-stage scientific research and drug discovery operations focused on identifying core disease mechanisms, identifying novel drug targets, and evaluating candidate molecules across dedicated laboratory facilities in major global research hubs.
- Development: Clinical trial management and regulatory submission operations conducting phase one through phase four human clinical trials worldwide to establish the safety, efficacy, and dosage profiles of experimental pharmaceutical compounds.
equipe executiva do Novartis AG
- Vasant NarasimhanChief Executive Officer
- Victor BultoPresident of US
- Patrick HorberPresident of International
- Mukul MehtaChief Financial Officer
- Steffen LangPresident of Operations
- Paul PenepentHead of Group Financial Reporting and Accounting
- Sloan SimpsonGlobal Head of Investor Relations
- Karen L. HaleChief Legal & Compliance Officer
- Robert KowalskiChief People & Organization Officer
- Evan BeckmanGlobal Head of Translational Medicine at Novartis Institute for BioMedical Research
Últimas notícias sobre a Novartis AG
Novartis signs $7.8 billion Abogen RNA deal
United StatesNovartis wins Entresto patent lawsuit
United StatesNovartis remibrutinib succeeds in MS trials
United StatesNovartis Q2 sales rise 3% to $14.4 billion
United StatesNovartis to acquire Myricx Bio for up to $1.5B in cancer drug push
United StatesNovartis braces for major patent cliffs despite double-digit margin gains
United States
Histórico de dividendos
Dividendos por ação pagos pela Novartis AG , por ano fiscal.
| Ano fiscal | Intermediário | Final | Especial | Total |
|---|---|---|---|---|
| FY2026(até o momento) | — | — | — | $4.7730 |
| FY2025 | — | — | — | $3.9940 |
| FY2024 | — | — | — | $3.7400 |
| FY2023 | — | — | — | $3.4690 |
| FY2022 | — | — | — | $3.3570 |
Principais indicadores financeiros
Resultados divulgados pela Novartis AG , em USD.
- Cap. de mercado
- 298,1 bi
- Receita (TTM)
- 57,4 bi
- P/L
- 29.9
- LPA (diluído, TTM)
- 5.2
- Dividend yield
- 3.0%
- Margem de lucro
- 17.5%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 54,8 bi | 17,1 bi | 14,1 bi | |
| 51,7 bi | 14,5 bi | 11,9 bi | |
| 46,7 bi | 9,8 bi | 14,9 bi | |
| 43,5 bi | 7,9 bi | 7 bi |